Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q7Z2Z2
UPID:
EFL1_HUMAN
Alternative names:
Elongation factor Tu GTP-binding domain-containing protein 1; Elongation factor-like 1; Protein FAM42A
Alternative UPACC:
Q7Z2Z2; A6NKY5; B7Z6I0; Q9H8Z6
Background:
Elongation factor-like GTPase 1, also known as Elongation factor Tu GTP-binding domain-containing protein 1, Elongation factor-like 1, and Protein FAM42A, plays a crucial role in protein synthesis. It is involved in the biogenesis of the 60S ribosomal subunit and translational activation of ribosomes, facilitating the GTP-dependent release of EIF6 from 60S pre-ribosomes in the cytoplasm. This process is essential for activating ribosomes for translation competence, allowing 80S ribosome assembly, and facilitating EIF6 recycling to the nucleus for 60S rRNA processing and nuclear export.
Therapeutic significance:
Elongation factor-like GTPase 1's involvement in Shwachman-Diamond syndrome 2, characterized by hematopoietic abnormalities, exocrine pancreatic dysfunction, and skeletal dysplasia, highlights its potential as a therapeutic target. Understanding the role of Elongation factor-like GTPase 1 could open doors to potential therapeutic strategies for treating this autosomal recessive disorder.